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Delivering DNA damage is an established concept to
treat cancer, but the precise mechanisms that determine
whether or not this damage will kill tumor cells are poorly
understood. Many anticancer agents are known to pro-
duce DNA damage upon interaction with specific intra-
cellular targets (e.g., topoisomerases, DNA itself, and the
replication machinery). This damage, in turn, can pro-
duce catastrophic cell death owing to gross metabolic
dysfunction or initiate a programmed response (e.g.,
apoptosis) leading to the regulated death of the tumor
cell. Resistance to catastrophic death presumably re-
quires mutations that prevent the drug-target interaction,
whereas resistance to programmed cell death can also in-
volve effector defects that maintain viability despite sub-
stantial cellular damage. The relative impact of various
resistance mechanisms to clinical drug resistance is con-
troversial and few have been validated in naturally occur-
ring tumors.
Genetic factors that influence treatment sensitivity are
typically evaluated in established cancer cell lines treated
in vitro or as xenografts in immunocompromised mice.
However, cell culture studies fail to take into account the
complexity of the tumor microenvironment (i.e., survival
factors, hypoxia, normal cell interactions), which has
been shown to play an important role in the treatment re-
sponse (Graeber et al. 1996; Walker et al. 1997). More-
over, depending on the experimental readout for drug-in-
duced cell kill—such as short-term viability or
clonogenic survival—very different results may be ob-
tained (Brown and Wouters 1999). Although ectopic or
orthotopic tumor transplantation systems are certainly
better approximations of the physiological state of bona
fide human tumors, they still rely on cell lines that are
necessarily selected for vigorous proliferation and sur-
vival in culture. To our knowledge, there has been no
study demonstrating that cell lines recapitulate the treat-
ment sensitivity of primary tumors.
Of course, patient material is the most relevant setting
in which to study drug action. However, controlled hu-
man studies are often impractical and in general can only
achieve correlative information between specific genetic
changes to patient responses or overall survival. More-
over, many of these studies are inconclusive, perhaps be-
cause human tumors are highly heterogeneous or because
it is difficult to correlate mutations in individual genes to
treatment sensitivity in a tumor that may contain other
mutations in the same genetic program (Schmitt and
Lowe 1999). Indeed, different approaches have produced
remarkably different perceptions of the relative impact of
various resistance mechanisms on clinical outcome. For
example, the impact of crucial genes such as p53 and bcl-
2 on therapeutic outcome in patients is still under debate.
In principle, transgenic and “knockout” mouse models
could be used to circumvent many of the problems asso-
ciated with studies using cell lines or patient material. For
example, specific genetic alterations can be introduced
into the mouse germ line or into primary tumors to gen-
erate relatively defined tumors. A series of mice harbor-
ing spontaneous, but highly related, tumors can then be
treated at their natural site with identical regimens to
evaluate the impact of the genetic alteration on clinical
outcome. Because experimental strategies are not limited
by the same considerations applied to patients, studies us-
ing mouse models can achieve a much more direct and
controlled analysis of treatment sensitivity. Yet, although
transgenic mice have revolutionized our understanding of
the molecular basis of tumor development, their contri-
bution to our understanding of cancer therapy has been
minimal (e.g., see references in Schmitt et al. 1999, 2000;
Bearss et al. 2000; Omer et al. 2000). Our laboratory has
made a concerted effort to investigate whether transgenic
mouse models will be useful to identify determinants of
treatment sensitivity. Here, we describe implications of a
lymphoma model developed to study the genes and pro-
cesses that affect anticancer therapy in vivo. Given the
good approximation of corresponding human malignan-
cies by transgenic tumor models, our studies suggest that
these models will be useful in understanding the treat-
ment sensitivity of human cancers.
EXPERIMENTAL PROCEDURES
Mice and tumor monitoring. Eµ-myc transgenic mice
and INK4a/ARF–/–, Rb+/–, and p53–/– mice were crossed
and the offspring was genotyped by allele-specific poly-
merase chain reaction (PCR) (Jacks et al. 1992, 1994;
Serrano et al. 1996). Transgenic mice of the F1 generation
(hereafter referred to as controls; pooled from the differ-
ent crosses) or transgenics being heterozygous for the
named loci were monitored twice a week by palpation of
the prescapular and cervical lymph nodes (LN), whereby
“well palpable” lymphoma reflect LN enlargements of at
least 5 mm in the longest diameter. Blood samples were
obtained by tail artery bleeding. After red cell lysis, white
blood cells were counted in a hemocytometer. Blood
smears were fixed and stained according to a modified
Wright’s protocol using the Leukostat kit (Fisher Diag-
nostics). White blood cell counts >3 x 105/µl and de-
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tectability of cells with lymphoblastic morphology in the
peripheral blood smear were considered “leukemic.”
Lymphoma processing and characterization. After
CO2 euthanasia, LN were resected and either fixed in 4%
neutral-buffered formalin or minced in phosphate-
buffered saline (PBS) and filtered through a 35-µm nylon
mesh; 7-µm paraffin-embedded, formalin-fixed LN sec-
tions were stained with hematoxylin-eosin (HE) to evalu-
ate apoptotic cell morphology. Single cell suspensions
were plated on irradiated (30 Gy) feeder layer (2.5 x 105
NIH-3T3 cells/10-cm plate) in 45% Iscove’s modified
Eagle medium, 45% Dulbecco’s minimal essential
medium, 10% fetal bovine serum, 100 units/ml penicillin
and streptomycin, 4 mM L-glutamine, and 25 µM 2-mer-
captoethanol. Genomic DNA was isolated by proteinase
K digest after short-term culturing to eliminate contami-
nating normal cells.
In vitro treatments and short-term viability assays.
Viability of lymphoma cells was analyzed by Trypan
Blue dye exclusion. For short-term in vitro assays, 106 vi-
able lymphoma cells were plated in conditioned medium
(i.e., supernatant from irradiated NIH-3T3 feeder layers);
irradiation, adriamycin (ADR), or mafosphamide was ad-
ministered at the indicated doses; and viability was mea-
sured relative to untreated controls 24 hours later.
Retroviral transduction of Eµ-myc lymphoma cells.
Retroviral infections were performed using murine stem
cell virus (MSCV)-based vectors that encode green fluo-
rescent protein (GFP) 3´ of an internal ribosomal entry
site of a bicistronic message. The murine bcl-2 cDNA
was cloned into MSCV-GFP. Retrovirus was produced
using Phoenix packaging cells (G. Nolan, Stanford Uni-
versity, California) as described (Serrano et al. 1997) and
collected in B-cell medium; 3 ml of high-titer viral su-
pernatant containing 4 µg/ml polybrene (Sigma) was
passed through a 0.45-µm filter and supplemented with
50 µg/ml lipopolysaccharide from Salmonella ty-
phimurium (Sigma) to infect 5 x 106 exponentially grow-
ing lymphoma cells by spinoculation on feeder cells at
600 g for 10 minutes. The infection procedure was re-
peated three times every 8 hours. After 24 hours, GFP ex-
pression was assessed by flow cytometry (FACScalibur,
Becton Dickinson) to estimate the percentage of infected
cells. The transduced cell populations (typically >70%
GFP-positive) were either propagated in recipient mice or
used for subsequent in vitro assays.
Lymphoma reconstitution and in vivo treatment. Un-
cultured or retrovirally transduced lymphoma samples
were transplanted into genetically matched, nontrans-
genic 6–10-week-old female mice by tail vein injection
(106 viable lymphoma cells in PBS), and recipient mice
were palpated for tumor formation twice a week. When
tumors became well-palpable, γ-irradiation (IRR), ADR,
or cyclophosphamide (CTX) was applied as a single 6 Gy
total body, 10 mg/kg, or 300 mg/kg body weight in-
traperitoneal treatment, respectively, and mice were sub-
sequently monitored for treatment response.
Western blotting analysis and assessment of apopto-
sis ex vivo. Western blotting analysis of whole-cell lym-
phoma cell lysates was carried out as described (Schmitt
et al. 1999) using anti-p53 and antipoly(ADR-ribose)
polymerase (PARP) polyclonal antibodies. Activation of
caspases was detected by affinity labeling and Western
blotting analysis of lymphoma cell lysates preincubated
with the biotinylated tetrapeptide caspase inhibitors
DEVD-chloromethyl ketone and YVAD-acyloxymethyl
ketone, which mimic cleavage sites for active caspases.
Binding of the biotinylated peptides was visualized by
probing with a streptavidin-biotinylated horseradish per-
oxidase complex (Amersham) and a chemiluminescent
substrate (Faleiro et al. 1997). Electrophoretic separation
and visualization of internucleosomal DNA fragmenta-
tion (DNA laddering) of genomic lymphoma DNA sam-
ples were carried out as described previously (Lowe et al.
1993). Apoptotic DNA strand breaks of individual cells
were detected in freshly isolated, single-cell lymphoma
suspensions by a fluorescence-based TUNEL (terminal
deoxynucleotidyl transferase dUTP nick end-labeling)
assay, performed in accordance to the manufacturer’s
protocol (Boehringer Mannheim).
Statistical evaluation. Treatment response data reflect
the time between remission, i.e., shrinkage of a palpable
lymphoma to nonpalpability within 6 days after treat-
ment, and recurrent palpability of a LN enlargement (re-
lapse). Persistence of palpable LN within 6 days after
treatment is considered “no response” and reflects either
a “no change” (NC) situation or, in case of lymphomas
growing under treatment, a “progressive disease” (PD).
Individual time-to-relapse values were plotted in the Ka-
plan-Meier survival curve format, and the curves were
compared using the log-rank (Mantel-Cox) test.
RESULTS
Eµ-myc Lymphomas Respond to Therapy
Eµ-myc transgenic mice overexpress the c-Myc onco-
protein in B cells and develop pre-B or B-cell lymphoma
with associated leukemia by several months of age (Fig.
1A) (Adams et al. 1985; Harris et al. 1988). These mice
provide several features that make them a potentially at-
tractive system for studying drug-mediated cytotoxicity
in vivo: (1) Tumor burden can be easily monitored by LN
palpation or blood smears; (2) lymphomas are detectable
long before the animals succumb to the malignancy; (3)
high quantities of pure tumor cells can be extracted from
lymphoma-bearing mice; (4) treatment responses are not
biased by an immunocompromised environment; (5)
lymphoma cells can be cultured and transplanted into nu-
merous syngeneic (but nontransgenic) mice; and (6) the
histopathological and genetic features of Eµ-myc lym-
phomas closely resemble human non-Hodgkin’s lym-
phomas. 
To test whether Myc-induced lymphomas respond to
therapy, animals bearing well-palpable tumors (>50
mm3) in prescapular or cervical LN were treated with var-
ious anticancer regimens. We have chosen total-body
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IRR, the anthracycline ADR (a topoisomerase II in-
hibitor), and the oxazaphosphorin CTX (an alkylating
agent), because these therapies are known to be effective
against lymphoma/leukemia and are thought to have dis-
tinct resistance mechanisms. The tumor response is mea-
sured as time to relapse, the period from treatment-in-
duced disappearance of the lymphomas to the
re-appearance of a well-palpable tumor (Fig. 1B). A tu-
mor is considered “no remission” if the LN enlargement
persists despite treatment. In our scheme, mice are desig-
nated as in remission or “disease-free” if the tumor
shrinks to a nonpalpable level within 6 days of treatment.
Responses can be depicted as Kaplan-Meier curves
showing the percentages of mice that are in remission af-
ter treatment at a given time. The vast majority of Eµ-myc
lymphomas responded to therapy, albeit to a varying de-
gree (see Fig. 2A for CTX). Furthermore, the disease-free
time lasted in most cases longer than the observation pe-
riod of 100 days after achieving initial remission, reflect-
ing a cure from the malignancy.
A potential problem in studying lymphoma responses
to therapy in transgenic mice is that all B cells express the
myc transgene, which may account for unphysiological
treatment effects on the normal hematopoietic compart-
ment, and thereby could reduce the accuracy of the
model. Moreover, it is difficult to distinguish tumor re-
lapses from secondary malignancies. Therefore, we also
studied tumor responses using transplanted lymphomas
as outlined in Figure 1A. In principle, this strategy has the
following advantages: (1) Recipient mice are the same
age and sex, minimizing variation; (2) recipient mice are
not transgenic; therefore, relapsed tumors are necessarily
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Figure 1. The Eµ-myc mouse as a tractable model of lymphomagenesis and anticancer treatment sensitivity. (A) Generation of trans-
plantable, genetically controlled primary lymphomas. Eµ-myc transgenic mice develop B-cell lymphoma with palpable lymph-node
(LN) enlargements by several months of age; for monitoring of lymphoma development, the time between birth and first-time palpa-
bility of peripheral lymphomas is considered the “time to onset.” After CO2 euthanasia, enlarged LN were resected, minced, and fil-
tered in phosphate-buffered saline and subjected to further analysis or systemic transplantation by tail-vein injection into nontrans-
genic, genetically matched recipient mice. By crossing to mice harboring heterozygous disruptions of candidate collaborator genes
(knockout mice, [k.o.]), offspring carrying the heterozygous constellation develop lymphomas that might have lost the remaining
wild-type allele, making those lymphomas in fact null for the gene of interest. (B) Anticancer treatment of mice bearing reconstituted
lymphoma. At the time of LN palpability, a single dose treatment is systemically applied. Failure to shrink the peripheral LN to a non-
palpable stage reflects “nonresponsiveness,” whereas otherwise the time between non- to repalpability of the LN is considered the
“time to relapse.”
 Cold Spring Harbor Laboratory Press on January 31, 2014 - Published by symposium.cshlp.orgDownloaded from 
derived from the original tumor; (3) material from the
same tumor can be compared before and after treatment;
(4) the same primary tumor can be assessed for response to
different agents; (5) the same primary tumor can be as-
sessed for reproducibility of treatment responses in several
animals; and (6) the number of transgenic mice is reduced.
To determine the feasibility of this approach, lym-
phoma cells were harvested from transgenic mice harbor-
ing well-palpable LN, and 106 cells were immediately
transplanted into 6–10-week-old female C57BL/6 mice
by tail vein injection. Well-palpable lymphomas arose
typically within 2–3 weeks. Primary and transplanted tu-
mors appeared to be equally disseminated diseases and
were histologically indistinguishable (Schmitt et al.
2000). Upon tumor manifestation, animals were treated
in the same way as the transgenic mice. Primary and
transplanted tumors treated with CTX responded simi-
larly, whereby late relapses in the group of primary tu-
mor-bearing mice were most likely due to secondary,
transgene-driven malignancies (Fig. 2A). Furthermore,
identical treatments of the same individual lymphoma re-
constituted in several animals resulted in highly repro-
ducible responses (data not shown). Therefore, reconsti-
tuted lymphomas can reliably recapitulate the responses
of primary tumors. 
Eµ-myc Lymphomas Can Acquire Drug Resistance
In human patients, many initially responding tumors
become progressively less responsive after the first re-
lapse, thereby determining the ultimate fate of the patient.
Similarly, in the subset of mice that did not achieve a
long-term remission, repetitive treatments frequently
shortened remission periods when compared to the first
response and eventually resulted in resistance to any fur-
ther treatment (Fig. 2B). Therefore, monitoring the “time
to first relapse” in our system (Fig. 2A) seems to be a
good prognosticator for terminal failure to repetitive
treatments as well. Although drug-resistant tumors were
produced by repetitive treatments with the same drug,
they often became cross-resistant to other drugs with dis-
tinct primary mechanisms of action. For example, tumors
selected for resistance to CTX were invariably cross-re-
sistant to ADR (data not shown). We expect that the abil-
ity to model acquired drug resistance in vivo will facili-
tate a better understanding of this major clinical problem.
Anticancer Treatment Induces p53 and Promotes
Apoptosis In Vivo
An advantage of the Eµ-myc model is that large num-
bers of lymphoma cells can be isolated from peripheral
LN for biochemical analysis of therapy-induced death.
Since well-palpable, malignant LN have at least 50–100
times the volume of normal LN, they predominantly con-
sist of tumor cells, which minimizes effects of normal cell
contamination. We have taken advantage of these proper-
ties to identify cellular changes that occur in lymphoma
cells treated with DNA-damaging anticancer agents in
vivo. For example, the p53 tumor suppressor can be in-
duced by DNA damage leading to cell cycle arrest or
apoptosis (Kastan et al. 1991; Lowe et al. 1993). To de-
termine whether therapy activates p53 in Eµ-myc lym-
phomas in vivo, we injected a series of mice with 106
cells derived from the same lymphoma and allowed well-
palpable lymphomas to form. Tumor-bearing mice re-
ceived a single treatment, and LN were harvested 1, 2, or
4 hours later. Upon exposure to IRR or CTX, p53 protein
levels were strongly induced in a time-dependent manner
(Fig. 3A, top), whereby ADR activated p53 with a slower
kinetic, achieving maximal induction at about 8 hours
(data not shown). 
We also monitored these lymphomas for characteristic
features of apoptosis, including caspase activation, DNA
fragmentation, and morphological changes. Anticancer
treatment led to cleavage of the caspase substrate PARP
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Figure 2. Transplanted myc lymphomas preserve their biologi-
cal properties. (A) Mice harboring transplanted control lym-
phomas (dashed line) respond similarly to CTX compared to
transgenic animals with primary control lymphomas (solid line).
Plotted are the disease-free times (as time to relapse) in the Ka-
plan-Meier survival curve format after a single treatment with
CTX (nprim. = 22 and ntranspl. = 60, respectively). Note that late
“relapses” of the primary lymphoma group might be in fact sec-
ondary transgene-driven malignancies. (B) Transplanted lym-
phomas recapitulate the progressive loss of chemosensitivity in
cancer patients. Repetitive treatments (numbered as treatment
cycles) with total body IRR, ADR, or CTX of mice (numbers in-
dicate individual primary lymphomas) that relapsed to the initial
treatment typically result in shortened remission periods (time to
relapse) and finally in no response at all (as indicated as no
change [NC] or tumor growth under treatment, which is pro-
gressive disease [PD]). 
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(Kaufmann et al. 1993; Lazebnik et al. 1994), with kinet-
ics closely following that observed for p53 accumulation
(Fig. 3A, middle). Moreover, active caspases were de-
tected in treated lymphomas using biotinylated tetrapep-
tide inhibitors such as DEVD and YVAD (data not
shown). All treatments resulted in internucleosomal frag-
mentation of genomic DNA, a late event in apoptotic cell
death known as “DNA laddering” (Fig. 3A, bottom)
(Wyllie et al. 1992). Cells with fragmented DNA can be
quantified using a modified version of the TUNEL assay
that labels DNA strand breaks with fluorescein. Note that
the TUNEL reaction preferentially labels apoptotic cells
instead of cells undergoing necrosis or containing pri-
mary strand breaks directly caused by radiation or anti-
cancer drugs (Gorczyca et al. 1993). Using this assay, we
observed a 10–100-fold signal induction relative to the
untreated control in isolated lymphoma cells 4 hours af-
ter treatment (Fig. 3B).
To complement this analysis, cell death was examined
in situ using standard histological staining. Untreated LN
had small islands of cells with morpholgical features of
apoptosis, suggesting a relatively high rate of sponta-
neous apoptosis (Fig. 3C) (see Harris et al. 1988; Hsu et
al. 1995; Schmitt et al. 1999). However, IRR and CTX
treatment induced massive apoptosis throughout the LN
within 4 hours of treatment. As for p53 induction, the
amount of apoptosis was less dramatic for ADR (Fig.
3B,C). Hence, anticancer agents can induce p53 and pro-
mote apoptosis in Eµ-myc lymphomas in vivo.
The p53 Pathway and Treatment Sensitivity
Although p53 loss can impair treatment sensitivity in
many test systems, the extent to which p53 contributes to
treatment outcome of human tumors is not well estab-
lished. Several explanations may account for these dis-
crepancies, including the possibility that the role of p53 in
therapy depends on the cellular context, as well as tech-
nical difficulties to correctly assess p53 status or to un-
cover such a relationship in heterogeneous patient mate-
rial (for a detailed review, see Schmitt and Lowe 1999).
If p53 is in fact a key regulator of therapy-induced cell
death in vivo, then lymphomas lacking functional p53
should display a cell death defect upon exposure to treat-
ment. To test this hypothesis, we crossed Eµ-myc trans-
genic mice to mice harboring heterozygous targeted dis-
ruptions of either the p53, the INK4a/ARF, or the
retinoblastoma protein (Rb) locus (Fig. 1A) (Jacks et al.
1992, 1994; Serrano et al. 1996). Of note, the INK4a/ARF
mutation used here disrupts both ARF function, an up-
stream regulator of p53, and p16INK4a, which disables the
Rb tumor suppressor pathway (for review, see Sherr
1998), and recapitulates the gross deletions of the
INK4a/ARF locus frequently found in human cancer en-
tities. Lymphomas arising in p53+/– or INK4a/ARF+/–
mice invariably lost the wild-type p53 or INK4a/ARF al-
lele, respectively, whereas Rb+/–-derived lymphomas re-
tained the wild-type Rb allele. This approach of generat-
ing “loss-of-function” mutants intrinsically allows one to
monitor the impact of a disrupted gene on lymphoma on-
set, measured as time between birth and first-time palpa-
bility of enlarged LN (Fig. 1A). Recent studies have
shown that activated oncogenes signal to p53 via ARF (de
Stanchina et al. 1998; Zindy et al. 1998). Indeed, disrup-
tion of either p53 or the INK4a/ARF locus dramatically
accelerated myc-induced lymphomagenesis, whereas
Rb+/– status did not, implying that the ARF-p53 pathway,
rather than the p16INK4a-Rb axis, acts as a failsafe mech-
anism for myc-induced lymphomagenesis (for detailed
discussion, see Schmitt et al. 1999).
Primary myc-driven p53 null or INK4a/ARF null lym-
phomas provide a useful system to examine the impact of
these loci on treatment response. Since these tumors arise
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Figure 3. Anticancer treatment activates the apoptotic program
in vivo. (A) Time-course analysis of the apoptotic response in
mice reconstituted with a control lymphoma after either IRR (6
Gy total body dose), ADR (10 mg/kg body weight intraperi-
toneally), or CTX (300 mg/kg body weight intraperitoneally).
Lymphoma cells were isolated at the indicated time points and
subjected to Western blot analysis for p53 expression and
poly(ADP-ribose) polymerase (PARP) cleavage (arrow indi-
cates cleavage product) or to agarose gel electrophoresis of ge-
nomic DNA to visualize DNA laddering. (B) FITC-fluores-
cence-based TUNEL reaction to detect DNA strand breaks,
another hallmark of apoptosis, by flow cytometry of single-cell
suspensions derived from the same reconstituted control lym-
phoma untreated or 4 hr after treatment with IRR, ADR, or CTX.
Untreated cells as negative control (gray curve), treated samples
(black curve) as indicated. (C) Hematoxylin-eosin (HE)-stained
LN sections of lymphoma samples as in B. Note the extent of
chromatin condensation and nuclear morphology as the typical
hallmarks of apoptotic cell deaths in islands of spontaneous cell
death in the untreated sample and as a consequence of anticancer
treatment.
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spontaneously and can only be considered “isogenic” for
the depleted loci, analysis of multiple individual tumors
controls for the unknown genetic alterations arising in
these cells. Therefore, numerous control (i.e., Eµ-myc
lymphomas arising in a control genetic background),
INK4a/ARF null, and p53 null lymphoma cells were ei-
ther placed in short-term cultures in vitro or injected di-
rectly into genetically matched recipients where lym-
phomas were allowed to form. In short-term viability
assays, INK4a/ARF null and p53 null lymphomas were
highly resistant to various anticancer treatments.
Whereas very low doses of each treatment achieved
nearly quantitative killing of control lymphomas, more
than 50% of the INK4a/ARF null (Schmitt et al. 1999) or
p53 null lymphomas remained viable even at very high
doses (Fig. 4A).
To address short-term responsiveness in vivo, we ex-
amined white blood cell (WBC) counts in leukemic ani-
mals or evaluated LN several hours after systemic treat-
ment of mice bearing either control, INK4a/ARF or p53
null lymphomas with IRR, ADR, or CTX. Measuring
WBC counts in a time-dependent manner is a powerful
tool to assess short-term drug-induced effects in our sys-
tem (Fig. 4B). Again, control leukemias responded well,
resulting in a substantial drop of the relative WBC count
already after 4 hours (IRR and CTX; ADR delayed) and
virtually a clearing of the circulation from leukemic
blasts after 24 hours for all treatment types. In contrast,
p53 null leukemias disappeared with much slower kinet-
ics; 12 hours after treatment application, the relative
WBC count was at least tenfold higher compared to con-
trol leukemias at that time. However, p53 null leukemias
were not completely refractory to therapy, since we typi-
cally failed to detect leukemias at later time points (data
not shown). Similarly, in LN sections from mice harbor-
ing p53 null lymphomas, spontaneous cell death was ab-
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Figure 4. Short-term response to anticancer treatment dependent on the p53 status. (A) 24-hr in vitro viability assay of freshly ex-
tracted control (solid line, squares) and p53 null (dotted line, diamonds) lymphoma cells treated with IRR, ADR, or mafosphamide
(MAF, a CTX analog active in vitro) at the indicated doses relative to untreated samples. (B) 24-hr in vivo time course of the white
blood cell (WBC) count in leukemic mice harboring either control (solid line, squares) or p53 null (dotted line, diamonds) lymphomas
after a single treatment as indicated relative to the initial WBC count. (C) HE-stained LN sections of a reconstituted p53 null lym-
phoma untreated or 4 hr after treatment with IRR or CTX (arrow points to a single dying cell with apoptotic morphology); compare
to Fig. 3C.
 Cold Spring Harbor Laboratory Press on January 31, 2014 - Published by symposium.cshlp.orgDownloaded from 
rogated, and virtually no cell death was detectable 4 hours
after treatment with IRR or CTX (Fig. 4C; compare to
Fig. 3C). The short-term in vivo response curves of mice
harboring INK4a/ARF null leukemias and the extent of
cell death in their LN sections several hours after treat-
ment with CTX were found to be similar to p53 null lym-
phomas (Schmitt et al. 1999).
Candidate Genes Can Be Introduced into Primary
Lymphomas and Studied In Vivo
Due to the possibility that loss of the remaining wild-
type allele in INK4a/ARF+/– or p53+/– lymphomas may
occur at a relatively early stage in lymphomagenesis, the
established malignancies might biologically differ more
substantially from controls than only in their INK4a/ARF
or p53 status, respectively. Therefore, we developed a
protocol to rapidly and efficiently infect primary lym-
phomas with MSCV-based retroviral vectors encoding a
test gene in conjunction with GFP on a bicistronic mes-
sage or GFP alone. Using this approach, gain-of-function
activities—or dominant-negative derivatives—can be in-
troduced along with empty vector controls into a series of
primary lymphomas to generate “matched pairs” differ-
ing only in the status of the test gene (Fig. 5A). Lym-
phomas infected with the empty vector or a candidate re-
sistance gene—here, the proto-oncogene bcl-2–can be
monitored for infection efficacy by flow cytometric GFP
expression analysis. Moreover, in vivo formation, main-
tenance, or selection of a (partially) GFP-positive (and si-
multa-neously test gene expressing) transplant malig-
nancy can be addressed by flow cytometric analysis of
re-extracted lymphoma cells (Fig. 5B) or by fluorescence
microscopy of leukemic blood smears (Fig. 5C).
Cell Culture Establishment Alters Treatment
Sensitivity In Vitro
Using the retroviral gene-transfer strategy outlined in
Figure 5A, we generated a series of primary lymphomas
expressing GFP alone or together with Bcl-2 and con-
firmed in this “matched pair” setting that overexpression
of Bcl-2 could protect from drug-induced cell death in
short-term viability assays (Schmitt et al. 2000). How-
ever, when these freshly harvested lymphomas were sub-
jected to continuous culturing for 4 weeks, the relative
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Figure 5. Retroviral gene transfer into primary myc lymphomas. (A) Technical outline. Freshly harvested primary lymphomas are sub-
jected to short-term culture in two identical aliquots. Using the murine stem cell virus (MSCV) optimized to drive long-term gene ex-
pression in B cells (Prince and Rigby 1991), a test gene in conjunction with GFP on a bicistronic message or GFP alone can be effi-
ciently introduced into lymphoma cells within 4 days. Upon infection, lymphoma cells can be transplanted into recipient animals. (B)
Infection efficacy (here with MSCV-GFP as control [ctrl.] and MSCV-bcl-2-GFP [bcl-2]) can be monitored by flow cytometric as-
sessment of green fluorescence before (pre) transplantation. After tumor formation (post), similar percentages of GFP-positive lym-
phoma cells can be isolated from the animals, underlining that there is no in vivo selection against GFP. (C) Visualization of GFP-ex-
pressing lymphoma cells in vivo. Blood smear (Wright’s stain, left) of a leukemic recipient of MSCV-GFP infected lymphoma cells
using fluorescence microscopy (right).
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impact of Bcl-2 on drug sensitivity was dramatically re-
duced. This effect was due to the fact that control lym-
phomas rapidly acquired resistance to anticancer treat-
ment simply by serial passaging in culture (Schmitt et al.
2000). The dramatic change in treatment sensitivity pro-
duced by cell culture establishment of lymphomas raises
general concerns about the use of cell lines to study drug
action.
Classic Clonogenic Survival Assays Fail to Detect
Apoptosis-related Chemoresistance
Since short-term viability assays do not measure over-
all survival but examine a “snapshot” in time, it is for-
mally possible that alterations that score in these assays
may only delay cell death. In contrast, clonogenic sur-
vival assays measure long-term proliferative capacity of
treated cells and, hence, have often been considered the
“gold standard” for in vitro assessment of chemosensitiv-
ity (Brown and Wouters 1999). For example, although
Bcl-2 can suppress cell death in short-term assays, sev-
eral groups have shown that Bcl-2 does not reduce drug-
induced cell kill in clonogenic survival assays (Yin and
Schimke 1995; Lock and Stribinskiene 1996; Kyprianou
et al. 1997; Schmitt et al. 2000). Indeed, these observa-
tions have questioned the relative importance of apopto-
sis on treatment sensitivity. 
Using matched pairs of primary lymphoma cells dif-
fering only in their Bcl-2 status, we have provided evi-
dence that the failure of Bcl-2 to enhance cell “survival”
may result from several technical caveats of the assay.
First, we demonstrated that Bcl-2 did not enhance clono-
genic survival following drug treatment of primary lym-
phomas under standard conditions, but revealed modest
protective function when the assay was performed in the
presence of interleukin-7 (Schmitt et al. 2000). This is
consistent with previous reports that survival factors pro-
vided by the natural tumor microenvironment can influ-
ence the ability of Bcl-2 to block cell death (Walker et al.
1997). Those factors are probably insufficient or absent at
the very low cell densities and the single cell type setting
of a standard clonogenic assay. Second, we noticed that
clonal outgrowth of primary tumor cells seeded at a
clonogenic density is already extremely poor in the ab-
sence of any drug (Schmitt et al. 2000). This suggested
that colonies might be escape mutants that already pos-
sessed an apoptotic defect with activities similar to those
of Bcl-2, making comparisons between expressing and
nonexpressing samples noninformative. In fact, reverse
transcriptase-PCR (RT-PCR) sequencing detected p53
mutations in more than half of the clones tested (Schmitt
et al. 2000). Finally, our in vivo analyses clearly showed
that Bcl-2 can promote drug resistance and tumor cell sur-
vival following drug treatment (see below).
Genetic Defects of the Apoptotic Machinery Reduce
Disease-free Survival upon Anticancer Treatment
Using different approaches—crosses to knockout mice
generating loss-of-function mutants as well as retroviral
gene transfer producing gain-of-function mutants—to
evaluate the contribution of p53-mediated apoptosis to
treatment outcome, we established a profound relation-
ship between apoptotic function and disease-free survival
in vivo. To assess long-term responses, animals harbor-
ing control, INK4a/ARF, or p53 null lymphomas were
treated with CTX and monitored for remission and re-
lapse by peripheral LN palpation (Fig. 1B). Control lym-
phomas responded extremely well to CTX and about 70%
remained in remission during the 100-day observation
period (Fig. 6, top). In statistically highly significant con-
trast, INK4a/ARF and p53 null tumors displayed an ex-
tremely poor long-term result to CTX. Despite initial re-
sponses, only 1/14 p53 null and 4/35 INK4a/ARF null
lymphomas remained in remission, and most of the re-
lapses occurred already within 40 days after drug admin-
istration (Fig. 6, top). We never detected loss of the re-
maining wild-type INK4a/ARF allele in relapsed “double
knockout” p53 null/INK4a/ARF+/– lymphomas (C.
Schmitt and S. Lowe, unpubl.), implying that INK4a/ARF
mutations can compromise therapy outcome, in part, by
disabling p53 (Schmitt et al. 1999).
Infection with an “empty vector” control did not inter-
fere with the excellent response of control lymphomas to
CTX, here achieving a long-term remission in about 65%
of the mice (Fig. 6, bottom). However, about 80% of the
mice harboring Bcl-2 overexpressing lymphomas failed
to respond initially to CTX, and the small fraction of re-
506 SCHMITT ET AL.
Figure 6. Long-term response to anticancer treatment of mice har-
boring genetically controlled lymphomas. Kaplan-Meier curves
for disease-free survival (time to relapse) of mice being transplated
with ctrl. (solid line), INK4a/ARF null (dots), or p53 null (dashes)
lymphomas (top; n = 60, 35, and 14, respectively) or harboring ei-
ther MSCV-GFP (ctrl.; solid line) or MSCV-bcl-2-GFP (bcl-2;
dashed line) infected control lymphomas (bottom; n = 17 and 20,
respectively) after a single treatment with CTX. (Reprinted, with
permission, from Schmitt et al. 1999 [copyright Cold Spring Har-
bor Laboratory Press] and from Schmitt et al. 2000 [copyright Na-
ture Publishing Group.] http://www.nature.com.)
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sponding animals had only very short disease-free sur-
vival periods (Fig. 6, bottom) (Schmitt et al. 2000).
Therefore, Bcl-2 seems to act as a potent drug resistance
gene if assessed in a model capable of reflecting the com-
plexity of a whole organism and the interactions of a tu-
mor with environmental factors at its natural site.
DISCUSSION
The Eµ-myc Model Is a Physiological Test System to
Study the Genetics of Chemoresistance
Although the biological and genetic determinants of
chemosensitivity are typically studied in established cell
lines, it is not obvious whether these systems accurately
reflect or predict the treatment response of bona fide tu-
mors. In this paper, we show that aspects of chemosensi-
tivity relevant in vivo can be missed using cell lines or
certain in vitro assays, and we present an in vivo model to
study responses of spontaneous tumors treated at their
natural site. Our system is based on the Eµ-myc trans-
genic mouse, which develops B-cell lymphomas that re-
semble closely human non-Hodgkin’s lymphomas with
respect to their histopathological properties and clinical
behavior in response to treatment. For example, treatment
of mice harboring control lymphomas with various anti-
neoplastic treatments produces in most cases long-lasting
remissions. As in patients, tumors that relapse typically
display a progressive shortening of subsequent remission
periods under repetitive treatments. Moreover, in Eµ-myc
lymphomas, disruption of p53 function severely reduced
treatment sensitivity and long-term responses (Schmitt et
al. 1999). This is in good agreement with clinical findings
relating p53 mutations to drug resistance in human hema-
tologic malignancies (El-Rouby et al. 1993; Wattel et al.
1994; Ichikawa et al. 1997; Wilson et al. 1997; Navarat-
nam et al. 1998; Moller et al. 1999). Hence, the informa-
tion we obtain from this model should be applicable to
human cancer.
The extent to which findings from animal models can
be extrapolated to the human condition has been the sub-
ject of much debate, although most of these concerns re-
late to technical limitations of a specific model (Berger
1999; Bibby 1999; Fiebig et al. 1999; Rudmann and
Durham 1999). The major power of our system is the
ability to use transgenic mouse methods and gene trans-
fer protocols to engineer tumors with specific genetic le-
sions, and then study the treatment sensitivity of a series
of these tumors in vivo. This approach achieves a general
homogeneity of clinical material that vastly exceeds that
possible in human clinical trials. At the same time, the
ability to treat a series of mice harboring independent but
related tumors recapitulates the unique character of indi-
vidual tumors in a patient population and presents a more
realistic picture of treatment sensitivity than repetitive
treatments of the same tumor cell line in xeno- or allo-
graft settings. In contrast to other new models using sur-
gical orthotopic implantation of primary tumor material
(for review, see Hoffman 1999), the Eµ-myc model is an
easy to handle system and allows statistically meaningful
data to be generated in a relatively cost-effective way.
Treatment Sensitivity Relies on Intact
Apoptotic Pathways
By studying the impact of genes on treatment sensitiv-
ity in the Eµ-myc model, we provide important insights
into the genetic mechanisms of chemoresistance. First,
our data underscore the notion that apoptosis is important
for treatment sensitivity and that disruption of apoptosis
is an important mechanism of chemoresistance. Second,
we demonstrate that disruption of apoptosis is a true mul-
tidrug resistance mechanism, since lesions in the apop-
totic program produced similar reductions in sensitivity
to different treatments (e.g., alkylating agent vs. irradia-
tion). Third, we have shown that mutations that disable
apoptosis during tumor development can simultaneously
coselect for drug resistance, even in the absence of any
prior treatment. For example, lymphomas arising as p53
null tumors not only formed much faster than their p53+/+
counterparts, but also responded much worse to a single
dose treatment. Finally, we have established the impor-
tance of p53 for treatment sensitivity in a physiological
setting and shown that disruption of components of the
p53 pathway can produce treatment resistance even in the
presence of wild-type p53 genes. This highlights the
problem that clinical studies classifying tumors strictly
on p53 status might overlook p53 pathway defects as a
potential cause of drug resistance despite the absence of
p53 mutations.
Genes Contribute to the Probability of a Given Cell
to Undergo Drug-mediated Cell Death
Although tumors overexpressing Bcl-2 or lacking the
INK4a/ARF or p53 genes displayed very poor long-term
responses to therapy, only Bcl-2 overexpression rendered
lymphomas nonresponsive to treatment. Particularly
when treated with CTX, most INK4a/ARF or p53 null
lymphomas ultimately achieved substantial tumor reduc-
tions that could even be classified as a “complete re-
sponse,” since the enlarged LN and associated leukemias
often completely disappeared, albeit with delayed kinet-
ics compared to control tumors. Nevertheless, almost all
of these tumors relapsed, indicating the presence of resid-
ual disease. Of note, we ruled out the possibility that these
relapses could originate from lymphoma cells that sur-
vived in compartments not accessible for CTX, since to-
tal body IRR produced treatment failures of p53 null and
INK4a/ARF null lymphoma-bearing animals as well (C.
Schmitt and S. Lowe, unpubl.).
How can we explain that a mutation accounts for short-
ened remission periods, although a treatment can achieve
a complete remission irrespective of this mutation in
vivo? Drug-induced cell death is a dynamic phenomenon
occurring at a stochastic likelihood in a cell population: A
susceptible fraction of the tumor will eventually die based
on (1) the locally effective drug dose (after drug delivery
and pretumoral metabolism); (2) the ability of the treat-
ment to kill in a specific (apoptosis) and nonspecific man-
ner (necrosis, catastrophic death) or to initiate other spe-
cific cellular response programs (e.g., long-term arrest);
and (3) the condition of any given cell (cellular fitness)
depending on previously influencing factors (hypoxic
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conditions, survival factors provided by surrounding
cells, etc.). In other words, the key question is: When, if
at all, will each individual cell of a tumor exposed to
treatment die? Following up on a model previously pro-
posed based on observations in p53-deficient mouse em-
bryo fibroblasts (Lowe et al. 1993), we understand the
role of p53 in anticancer treatment response as a regula-
tor to facilitate cell death upon sensitization by DNA
damage. In this—necessarily oversimplified—“probabil-
ity-to-die” model, the efficiency of a drug to kill at a
given time is plotted as a dose-dependent probability to
die (Fig. 7). This correlation between dose and cell death
follows a sigmoid-shaped distribution function. Although
functional p53 promotes drug-induced death, loss of p53
shifts this curve to the right, making it less likely for a cell
to die from the same dose. Importantly, by controlling the
death probability in any individual cell in response to a
given amount of damage, genes control the rate of cell
death in the entire tumor cell population. Reflecting the
same stochastic model, the efficiency of a treatment to
destroy a tumor mass facing a constant amount of damage
follows a sigmoid-shaped time-dependent distribution
function. Thus, the reduced likelihood of a p53 null cell
to die results in a slower tumor reduction in a p53-defi-
cient malignancy or, in turn, requires higher doses to
achieve death rates comparable to p53 wild-type tumors.
Since dose escalation is limited by general anticancer
drug-related toxicity as well as drug-specific side effects,
the administered dose cannot exceed the therapeutic win-
dow, which is the dose range between a tumor-effective
and an intolerably toxic drug dose.
As seen in several examples in this paper, different
treatments work in different therapeutic windows with re-
spect to the p53 status: IRR or CTX substantially de-
creased the number of p53 null lymphoma cells in circu-
lation, whereas no reduction was observed in the same
period for treatment with ADR (see Fig. 4B). Therefore,
different treatments kill in their specific therapeutic win-
dows in a mostly p53-dependent manner, a partially p53-
independent or even an almost p53-independent manner
(Fig. 7). According to this model, a more p53-indepen-
dent treatment like CTX can even kill log-ranks of cells
in a p53-deficient tumor but cannot prevent the very small
fraction of remaining cells to cause the clinical relapse.
If genetic lesions within a tumor affect the probability
that a tumor cell will finally die within a certain exposure
time or dose of damage, then three other parameters be-
come important: drug half-life, tumor regrowth rate, and
alternative cellular response programs. Although drug
half-life and tumor regrowth are exactly the factors al-
lowing a p53-deficient tumor to die slowly enough to
emerge from the remaining viable population when no
drug is effective anymore, alternative response programs
add more complexity to the model. For example, it is
known that tumor cells can undergo a long-term arrest in
response to DNA damage but may still be able to re-enter
the cell cycle (Di Leonardo et al. 1994). In fact, we ob-
served that Bcl-2 overexpressing lymphomas, which typ-
ically failed to regress upon treatment, progressed very
slowly until they eventually killed the tumor-hosting ani-
mal (C. Schmitt and S. Lowe, unpubl.). Furthermore, this
behavior seems to be due to a p53-dependent cell cycle
arrest, since mice harboring p53 null Bcl-2 overexpress-
ing lymphomas rapidly reached a terminal stage after un-
successful treatment (C. Schmitt and S. Lowe, unpubl.).
Although their functions only partially overlap—Bcl-2
strictly antiapoptotic, p53 controlling apoptosis and ar-
rest—the effect on the probability-to-die model is syner-
gistic for Bcl-2 overexpression and loss of p53 function,
since both promote a slower death rate in the tumor pop-
ulation, which, in turn, is the basis for relapses. Although
this model certainly highlights only selected aspects of
drug sensitivity and resistance, it is in good agreement
with our in vivo observations and typical clinical courses
of patients under chemotherapy. 
PERSPECTIVE: MOUSE MODELS AND
CANCER THERAPY
We believe that physiological mouse model systems
such as the Eµ-myc transgenic mouse provide a useful
“bridge” between cell-line-based systems and clinical
trials. Like cell line systems, these models are highly ma-
nipulatable. At the same time, they allow analysis of
drug action in realistic settings without the cost and eth-
ical considerations involved in patient trials. Mouse sys-
tems can be used to study the impact of specific genes on
treatment sensitivity, and, indeed, we have validated this
approach using Eµ-myc lymphomas harboring mutations
that are extremely common in human malignancies.In
addition, despite inevitable species-specific differences
between mice and humans, we expect that analysis of
treatment sensitivity in mice will establish general prin-
ciples that will apply to the human condition. Finally, the
unique ability to genetically engineer highly defined tu-
mors in mice will facilitate preclinical studies to evalu-
ate the action of novel compounds directed against spe-
cific genetic lesions.
508 SCHMITT ET AL.
Effective drug dose
Pr
ob
ab
ilit
y 
of
 c
el
l d
ea
th
Therapeutic
window
p53+/+ p53 null
Figure 7. Probability-to-die model of chemosensitivity and p53
status. Given a normally distributed likelihood for any individ-
ual cell exposed to the same local dose of an anticancer treat-
ment to die from that treatment within a certain time, a dose in-
crement will theoretically result in a higher fraction of killed
cells in the observed population. As discussed in the text, cells
lacking functional p53 (dashed line) have a decreased probabil-
ity of dying from the same local dose, but ideally still maintain
the dose-response characteristics of their p53 wild-type (solid
line) counterparts. A treatment applied within the therapeutic
window, the dose range between objective anticancer effects,
and the limitations due to toxic side effects in nonmalignant
compartments will therefore preferentially kill p53 wild-type
cells but, to a lesser extent, p53 null cells as well. Note that the
therapeutic window is a treatment-specific constant, making dif-
ferent treatments more or less p53-dependent.
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